Halaven
NICE rejects Eisai’s Halaven in earlier setting for metastatic breast cancer
February 22, 2018Sales and Marketing Brest cancer, Cancer, Eisai, Halaven, NICE, pharma
NICE has published its decision not to recommend Eisai’s Halaven (eribulin) in the treatment of locally advanced or metastatic breast …
NICE refuses Eisai’s breast cancer drug in new indication
November 28, 2017Manufacturing and Production, Sales and Marketing Cancer, Eisai, Halaven, NICE, breast cancer, pharma
NICE has announced that it has rejected Eisai’s Halaven (eribulin) through draft guidance advising not to use the drug in …
Top ten stories in the pharmaceutical industry this week
September 9, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, BMS, Celgene, Cloud Computing, Eisai, FDA, GSK, Halaven, Novartis, Novo Nordisk, Roche, Teva, agios, epipen, rheumatoid arthritis
It’s Friday, and that means it’s time for another run-down of the biggest stories on Pharmafile.com over the last week. …
Eisai “cannot understand” German agency’s recommendation to reject Halaven
September 6, 2016Manufacturing and Production, Research and Development Eisai, Germany, Halaven, IQWIG, german
Eisai has issued a statement to declare their “bewilderment” following a decision from the German Institute for Quality and Efficiency …
Eisai’s Halaven recommended for European approval
April 4, 2016Research and Development, Sales and Marketing Eisai, Halaven, liposarcoma
Eisai has received a positive opinion from the European Commission’s CHMP for Halaven (eribulin) as a second-line therapy for patients …
Eisai’s Halaven shown to restrict further cancer metastasis
December 11, 2015Research and Development, Sales and Marketing Eisai, Halaven, Merck, keytruda
New data presented by Eisai supports the previously shown ability of Halaven (eribulin) to reverse epithelial-to-mesenchymal transition, the process by …
NHS backtracks on Cancer Drugs Fund de-listings
March 12, 2015Sales and Marketing Afinitor, CDF, Cancer Drugs Fund, England, Halaven, NHS, Novartis, everolimus
NHS England is expected to perform a U-turn on several decisions to remove treatments from the cancer drugs fund when …
Merck and Eisai partner on cancer therapy trial
March 6, 2015Research and Development, Sales and Marketing Bayer, Cancer, FDA, Halaven, Lenvima, Merck, Stivarga, keytruda, oncology, pd1
Merck and Eisai are teaming up for collaborative trials to test the effects of using combinations of each company’s oncology …
Eisai cancer drug performs in sarcoma disease
February 26, 2015Sales and Marketing Cancer, Eisai, Halaven, eribulin, sarcoma, tumour
Eisai’s cancer drug Halaven met its primary endpoint and demonstrated overall survival benefit in two distinct solid tumour types in …
NHS drops 25 treatments from Cancer Drugs Fund
January 12, 2015Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus
Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …
Eisai restates Halaven’s challenge to Roche’s Xeloda
September 30, 2013Research and Development, Sales and Marketing ECC, Halaven, Roche, Xeloda
Eisai has updated research on its breast cancer drug Halaven in a renewed bid to establish the treatment as a …
UK at centre of Eisai plans
September 18, 2012Research and Development, Sales and Marketing CNS, Cancer Drugs Fund, Eisai, Fycompa, Halaven
Diseases of the central nervous system (CNS) and cancer will be the main areas targeted by Japanese firm Eisai as …
NICE rejects Halaven for breast cancer
April 3, 2012Sales and Marketing Eisai, Halaven, NICE, breast cancer
NICE has rejected Eisai’s novel breast cancer drug Halaven, due to concerns over its safety and costs. In its final …
NICE will not back Eisai’s Halaven
November 17, 2011Medical Communications, Sales and Marketing Eisai, Halaven, NICE, breast cancer
NICE has not recommended Eisai’s novel breast cancer drug Halaven due to concerns over its safety and cost.In draft guidance …
NICE says no to breast cancer treatment Halaven
July 20, 2011Sales and Marketing Eisai, Halaven, NICE
Eisai’s Halaven has been rejected by NICE in draft guidance for locally advanced or metastatic breast cancer. Halaven (eribulin) is …
Latest content
FibroFind appoints Lee Borthwick as CEO
